Omega Therapeutics Net Income
| OMGADelisted Stock | USD 0.05 0.01 21.25% |
As of the 15th of February 2026, Omega Therapeutics holds the Risk Adjusted Performance of 0.0537, coefficient of variation of 1837.69, and Semi Deviation of 23.86. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Omega Therapeutics, as well as the relationship between them.
Omega Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Omega Therapeutics' valuation are provided below:Omega Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Omega |
Search Suggestions
| OM | Outset Medical | Company |
| OM | MANTRA | Cryptocurrency |
| OMBXX | Aim Investment Secs | Money Market Fund |
| OMAH | VistaShares Target 15 | ETF |
| OMXHBGI | OMX Helsinki BenchmarkGI | Index |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Omega Therapeutics reported net income of (97.43 Million). This is 128.55% lower than that of the Biotechnology sector and 239.09% lower than that of the Health Care industry. The net income for all United States stocks is 117.06% higher than that of the company.
Omega Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omega Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omega Therapeutics could also be used in its relative valuation, which is a method of valuing Omega Therapeutics by comparing valuation metrics of similar companies.Omega Therapeutics is currently under evaluation in net income category among its peers.
Omega Fundamentals
| Return On Equity | -1.67 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (6.29) % | |||
| Current Valuation | 100.44 M | |||
| Shares Outstanding | 55.37 M | |||
| Shares Owned By Insiders | 1.60 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 5.21 M | |||
| Price To Book | 0.23 X | |||
| Price To Sales | 0.98 X | |||
| Revenue | 3.09 M | |||
| Gross Profit | (34.5 M) | |||
| EBITDA | (93.49 M) | |||
| Net Income | (97.43 M) | |||
| Cash And Equivalents | 173.66 M | |||
| Cash Per Share | 3.63 X | |||
| Total Debt | 128.43 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 13.46 X | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (91.51 M) | |||
| Short Ratio | 6.97 X | |||
| Earnings Per Share | (1.32) X | |||
| Target Price | 11.5 | |||
| Number Of Employees | 93 | |||
| Beta | 1.64 | |||
| Market Capitalization | 7.9 M | |||
| Total Asset | 204.37 M | |||
| Retained Earnings | (334.63 M) | |||
| Working Capital | 63.08 M | |||
| Net Asset | 204.37 M |
About Omega Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Omega Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omega Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omega Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Omega Stock
If you are still planning to invest in Omega Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Omega Therapeutics' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |